Peng Bo, Chen Hu, Lou Xiao
Int J Clin Pharmacol Ther. 2017 Dec;55(12):910-914. doi: 10.5414/CP203109.
Bortezomib is a landmark drug in the therapeutic history of multiple myeloma as the first-generation proteasome inhibitor. It is widely used clinically, and its common adverse reaction is peripheral nerve lesion. We observed a severe syndrome of inappropriate antidiuresis (SIAD) in a female patient with multiple myeloma treated with bortezomib. This paper reviews the treatment process and relevant research progress regarding SIAD through a case report so as to improve the clinicians' ability to recognize and diagnose this rare complication. .
硼替佐米作为第一代蛋白酶体抑制剂，是多发性骨髓瘤治疗史上的一种标志性药物。它在临床上被广泛使用，其常见的不良反应是周围神经病变。我们在一名接受硼替佐米治疗的多发性骨髓瘤女性患者中观察到了严重的抗利尿激素分泌失调综合征（SIAD）。本文通过病例报告回顾了SIAD的治疗过程及相关研究进展，以提高临床医生对这种罕见并发症的识别和诊断能力。
